A multicenter, randomized phase II study of second-line maximum androgen blockade with an alternative antiandrogen combined with tegafur-uracil (UFT) for prostate cancer with relapse after initial ...
London, 12 December 2006 -- Eighty-four percent of GPs and 76 percent of specialists (uro-oncologists or urologists) agree that there is a significant legal risk associated with off-label prescribing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback